Monthly pipeline update: August 2026

This August, the long-awaited approval of Lytenava (bevacizumab-vikg; Outlook Therapeutics) changed the landscape of neovascular age-related macular degeneration (AMD) treatment. Major updates in dry eye, lens technology, and glaucoma treatment also took the spotlight. Learn the latest in pipeline news from our roundup below: